Procter & Gamble Hygiene and Health Care Limited
Quality (79/100) does the heavy lifting; momentum (6/100) is the drag.
ExpensiveOvervaluedProcter & Gamble Hygiene and Health Care Limited earns a Sell from StocksWizard, with a blended score of 34/100. On 34.0x trailing earnings it sits pricier than the Consumer Defensive median of about 26.1x. It's sitting close to its 52-week low of ₹8,477. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹11,084 implies about 29% upside across 2 analysts. It clears 5 of 13 investability checks, with durability 79, valuation 27 and momentum 6 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹4,245.57.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-39.25% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell34Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 114.9%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -5%
- Fail: Earnings growing: -2%
- Pass: Net margin ≥ 10%: 20.0%
- Fail: Current ratio > 1.5: 1.22
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 19.41
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter70.9%
- Institutions14.7%
- Public & other14.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (114.9%).
- Lightly leveraged balance sheet.
- Healthy profit margin (20.0%).
- Financially solid — Altman Z 19.41.
Opportunities
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~38% above our estimated fair value.
About Procter & Gamble Hygiene and Health Care Limited
Procter & Gamble Hygiene and Health Care Limited manufactures and distributes branded consumer goods across India and internationally through two segments: Health care Products, which includes ointments, creams, cough drops, and tablets; and Hygiene Products, encompassing feminine hygiene items, skin care products, and feminine care pads.
Procter & Gamble Hygiene and Health Care Limited — frequently asked questions
Is Procter & Gamble Hygiene and Health Care Limited a buy, hold or sell?
StocksWizard currently rates Procter & Gamble Hygiene and Health Care Limited (PGHH) a Sell, based on a blended score of 34/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Procter & Gamble Hygiene and Health Care Limited's fair value?
Our blended DCF and relative-valuation model estimates Procter & Gamble Hygiene and Health Care Limited's fair value at about ₹5,306.97, versus a current price of ₹8,594 — roughly 38% downside. On that basis the stock looks overvalued by 38%.
Is Procter & Gamble Hygiene and Health Care Limited financially healthy?
Procter & Gamble Hygiene and Health Care Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Procter & Gamble Hygiene and Health Care Limited's share price performed?
Procter & Gamble Hygiene and Health Care Limited is down 15% over three months, and last traded at ₹8,594. Past performance doesn't predict future returns.
More in Consumer Defensive
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.